{"id":338546,"date":"2026-11-04T11:23:24","date_gmt":"2026-11-04T05:53:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/jenburkt-pharmaceuticals-q2-results-fy27-pat-10-crore\/"},"modified":"2026-11-04T11:23:24","modified_gmt":"2026-11-04T05:53:24","slug":"jenburkt-pharmaceuticals-q2-results-fy27-pat-10-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jenburkt-pharmaceuticals-q2-results-fy27-pat-10-crore\/","title":{"rendered":"Jenburkt Pharmaceuticals Q2 Results FY27: PAT Edges Up 0.49% To Rs 10.21 Cr, Revenue Rs 48.32 Cr, PAT Rs 10.21 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Jenburkt Pharmaceuticals Q2 Results FY27 were declared on 3 November 2026. Revenue increased 6.06% YoY to Rs 48.32 Cr from Rs 45.56 Cr, and net profit edged up 0.49% to Rs 10.21 Cr from Rs 10.16 Cr. The quarterly results therefore show YoY growth on both lines, though profit grew far more slowly than sales.<\/p>\n<\/div>\n

Jenburkt Pharmaceuticals Ltd (JENBURPH) Q2 Results FY27 announced on 3 November 2026, covering the company’s financial performance for the July to September quarter. The results date is 3 November, and the company reported revenue of Rs 48.32 Cr and net profit of Rs 10.21 Cr. Jenburkt Pharmaceuticals Q2 Results FY27 therefore describe a steady top line and an almost unchanged bottom line.<\/p>\n

The Jenburkt Pharmaceuticals Q2 Results results analysis that follows covers the financial highlights, the listed business factors, the FY27 outlook and the risks, built on figures that Univest compiled for the quarter. The Financial Highlights table comes straight after this introduction and anchors every comparison.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n